Clinical trials: High-dose Chemotherapy
Multiple Myeloma
Expanded Natural Killer (NK) Cells for Multiple Myeloma Study
High-dose chemotherapy with melphalan and autologous hematopoietic stem cell transplantation (HSCT) is considered standard treatment for patients with multiple myeloma.
- Trial name
- NCT01040026
- Testing
- Treatment with in vitro expanded haploidentical NK cells
- Where
- Switzerland
- Volunteers
- 10 people
- Sponsor
- University Hospital, Basel, Switzerland
Melanoma (Skin)
S0008: Chemotherapy Plus Biological Therapy in Treating Patients With Melanoma
RATIONALE: Interferon alfa may interfere with the growth of cancer cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00006237
- Testing
- interleukin-2, filgrastim, interferon alfa
- Where
- 297 sites in United States, Australia
- Volunteers
- 432 people
- Sponsor
- SWOG Cancer Research Network
Acute Myeloid Leukemia, Pediatric Cancer
Uproleselan With Pre-Transplant Conditioning in Hematopoietic Stem Cell Transplantation for AML
This research study is studying a new drug, uproleselan, to see if it is safe and effective in decreasing relapse after stem cell transplant and improving leukemia-free survival in pediatric patients with acute myeloid leukemia…
- Trial name
- NCT05569512
- Testing
- Uproleselan, Fludarabine, Clofarabine
- Where
- 5 sites in United States
- Volunteers
- 1 people
- Sponsor
- Malika Kapadia
Solid Tumor, Adult Central Nervous System Germ Cell Tumor
Busulfan, Melphalan, Topotecan Hydrochloride, and a Stem Cell Transplant in Treating Patients With Newly Diagnosed or Relapsed Solid Tumor
RATIONALE: Giving high-dose chemotherapy before an autologous stem cell transplant stops the growth of tumor cells by stopping them from dividing or killing them.
- Conditions
- Solid Tumor, Adult Central Nervous System Germ Cell Tumor, Adult Rhabdomyosarcoma, Childhood Central Nervous System Germ Cell Tumor
- Trial name
- NCT00638898
- Testing
- busulfan, melphalan, topotecan hydrochloride
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- City of Hope Medical Center
Hodgkin Disease, Hodgkin's Lymphoma
Gemcitabine and Hodgkin's Disease Chemotherapy Followed by Peripheral Blood Stem Cell Rescue for Hodgkin's Disease
This is a phase 2 study of gemcitabine + high-dose chemotherapy followed by peripheral blood stem cell (PBSC) rescue for Hodgkin's Disease
- Conditions
- Hodgkin Disease, Hodgkin's Lymphoma, Lymphoma
- Trial name
- NCT00388349
- Testing
- Gemcitabine, Vinorelbine, Carmustine
- Where
- United States
- Volunteers
- 146 people
- Sponsor
- Stanford University
Multiple Myeloma and Plasma Cell Neoplasm
Chemotherapy Plus Peripheral Stem Cell Transplant in Treating Patients Who Have Multiple Myeloma or Primary Systemic Amyloidosis
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplant may allow the doctor to give higher doses of…
- Trial name
- NCT00007995
- Testing
- filgrastim, recombinant interferon alfa, sargramostim
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- Herbert Irving Comprehensive Cancer Center
Ovarian Cancer, Relapses
Trial of High Dose Topotecan With Carboplatin in Patients With Relapsed Ovarian Carcinoma
The early relapse of ovarian cancer occurring within 6 months of chemotherapy including platinum regimen are called relapses 'platinum resistant' consecutively patients die quickly of their disease.
- Trial name
- ITOV04 (NCT01177501)
- Testing
- Topotecan
- Where
- France
- Volunteers
- 3 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Osteosarcoma, Spindle Cell Sarcoma of Bone
Will Glucarpidase After Methotrexate Treatment for Bone Sarcoma Lead to Fewer Side Effects and Reduce Chemotherapy Delays?
Methotrexate is one of the most effective chemotherapy drugs in the treatment of osteosarcoma and some other types of bone sarcoma which are treated the same way as osteosarcoma.
- Trial name
- NCT02022358
- Testing
- Glucarpidase, Methotrexate, Folinic Acid
- Where
- United Kingdom
- Volunteers
- 34 people
- Sponsor
- University College, London
Neuropathic Chronic Pain
Assessing the Efficacy of a High-Dose Lidocaine-Tetracaine Cream for the Treatment of Peripheral Neuropathic Pain
The goal of this clinical trial is to learn if the topical anesthetic cream works to treat neuropathic chronic pain in older adults who have not found sufficient relief undergoing other pain treatments and/or medications.
- Trial name
- NCT07396129
- Testing
- Lidocaine (23%) + Tetracaine (7%)
- Volunteers
- 30 people
- Sponsor
- Pontificia Universidad Catolica de Chile
Brain Tumors
Tandem High Dose Chemotherapy and Autologous Stem Cell Rescue for High Risk Pediatric Brain Tumors
The investigators plan to improve event free survival rate and reduce treatment related toxicities of pediatric patients with high risk/recurrent CNS tumors by administrating tandem high dose chemotherapy and autologous stem cell…
- Trial name
- NCT01342237
- Testing
- HDCT 1(TTC), HDCT2(MEC)
- Where
- South Korea
- Volunteers
- 33 people
- Sponsor
- Seoul National University Hospital
Lymphoma, HIV
Autologous Transplant in HIV Patients (BMT CTN 0803)
This study is a Phase II, multicenter trial assessing overall survival after autologous hematopoietic stem cell transplantation using a BEAM transplant regimen (carmustine, etoposide, cytarabine, melphalan) in lymphoma patients…
- Trial name
- NCT01141712
- Testing
- Autologous transplant, BCNU, Etoposide
- Where
- 16 sites in United States
- Volunteers
- 43 people
- Sponsor
- Medical College of Wisconsin
Lymphoma
Rituximab and Combination Chemotherapy in Treating Patients With Newly Diagnosed, HIV-Associated Burkitt's Lymphoma
RATIONALE: Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread.
- Trial name
- NCT00392834
- Testing
- filgrastim, pegfilgrastim, rituximab
- Where
- 13 sites in United States
- Volunteers
- 34 people
- Sponsor
- AIDS Malignancy Consortium
Drug/Agent Toxicity by Tissue/Organ, Leukemia
Growth Factor to Prevent Oral Mucositis in Patients With Hematologic Cancer
RATIONALE: Keratinocyte growth factor may prevent symptoms of mucositis in patients receiving radiation therapy and chemotherapy.
- Conditions
- Drug/Agent Toxicity by Tissue/Organ, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00004132
- Testing
- filgrastim, palifermin, cyclophosphamide
- Where
- United States
- Sponsor
- Jonsson Comprehensive Cancer Center
Follicular Lymphoma
BENdamustine at Elevated Dose for Relapsed Follicular Lymphoma in Intensification Therapy and Transplantation (BENEFIT)
The purpose of this study is to evaluate the efficacy and safety of BeEAM (bendamustine, etoposide, cytarabine and melphalan) regimen prior to autologous stem cell transplant for first and second chemosensitive relapses in…
- Trial name
- BENEFIT (NCT02008006)
- Testing
- BeEAM
- Where
- 13 sites in France
- Volunteers
- 21 people
- Sponsor
- Centre Leon Berard
Cerebral Lymphoma B Cell Refractory
Phase II Study Evaluating a Combination of Pegylated Liposomal Doxorubicin and Dexamethasone for the Treatment of Immunocompetent Patients With Cerebral Lymphoma Relapsed or Refractory to First-line Chemotherapy With High Dose Methotrexate (MTXHD) and / or High-dose Cytarabine.
The protocol is to assess the overall response rate (complete response and partial response) of treatment with non-pegylated liposomal doxorubicin at a dose of 50 mg / m² in combination with dexamethasone in immunocompetent adult…
- Trial name
- MYLY (NCT01848652)
- Testing
- infusion of MYOCET
- Where
- 3 sites in France
- Volunteers
- 5 people
- Sponsor
- University Hospital, Brest
Oral Mucositis in Patients Undergoing HSCT
A Phase III Study of Efficacy of Lactobacillus CD2 Lozenges in Preventing High-Dose Chemotherapy Induced Oral Mucositis in Patients Undergoing Myeloablative Hematopoietic Stem Cell Transplantation
The study will be conducted at departments of Medical Oncology and Hematology, All India Institute of Medical Sciences (AIIMS). Patients with various malignancies who are taken up for high dose chemotherapy followed by stem cells…
- Trial name
- mucositis (NCT01797952)
- Testing
- Lactobacillus CD 2
- Where
- India
- Sponsor
- All India Institute of Medical Sciences
Leukemia, Myeloid, Acute
NLA101 in Adults Receiving High Dose Chemotherapy for AML
Phase 2 open-label, multi-center, randomized, controlled, dose-finding study of safety and efficacy of NLA101 to reduce the rate of infections associated with CIN in adult subjects with AML.
- Trial name
- LAUNCH (NCT03301597)
- Testing
- NLA101, Standard of Care (SOC) chemotherapy
- Where
- 36 sites in United States, Australia and 1 more
- Volunteers
- 146 people
- Sponsor
- Nohla Therapeutics, Inc.
Ovarian Cancer
Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Stage III or Stage IV Ovarian Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of…
- Trial name
- NCT00003297
- Testing
- mitoxantrone hydrochloride, thiotepa, topotecan hydrochloride
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Georgetown University
Multiple Myeloma
A Study of Bortezomib, Cyclophosphamide, and Dexamethasone in Patients With Untreated Multiple Myeloma and Planned for a High Dose Chemotherapy
The purpose of this study is to evaluate the safety and effectiveness of bortezomib in combination with a standard regimen of cyclophosphamide and dexamethasone.
- Trial name
- NCT00833560
- Testing
- Cyclophosphamide, Bortezomib, Dexamethasone
- Where
- 34 sites in Germany
- Volunteers
- 401 people
- Sponsor
- Janssen-Cilag G.m.b.H
Mantle Cell Lymphoma
Intensive Induction Therapy Followed by High Dose Chemo and BM Transplant for Mantle Cell Lymphoma
Patients with mantle cell lymphoma have a grave prognosis. They usually have an initial response to therapy, however progress early in the course of the disease and have very poor survival.
- Trial name
- NCT00586755
- Testing
- Intensive Induction-BMT
- Volunteers
- 48 people
- Sponsor
- Duke University